An overview of small-molecule agents for the treatment of psoriasis

This publication has 136 references indexed in Scilit:

• Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL‐17A ( LY3509754 ): A Phase I Randomized Placebo‐Controlled Study
  Clinical Pharmacology & Therapeutics, 2024
• Cedirogant Population Pharmacokinetics and Pharmacodynamic Analyses of Interleukin‐17A Inhibition in Two Phase 1 Studies in Healthy Participants and Participants with Moderate to Severe Psoriasis
  Clinical Pharmacology in Drug Development, 2024
• Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
  BioDrugs, 2023
• Deucravacitinib for the Treatment of Psoriatic Disease
  American Journal of Clinical Dermatology, 2022
• Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review
  American Journal of Clinical Dermatology, 2020
• Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
  JAMA, 2020
• Dermatologist and Patient Preferences in Choosing Treatments for Moderate to Severe Psoriasis
  Dermatology and Therapy, 2017
• Novel Oral Therapies for Psoriasis and Psoriatic Arthritis
  American Journal of Clinical Dermatology, 2016
• Mitochondrial and caspase pathways are involved in the induction of apoptosis by IB-MECA in ovarian cancer cell lines
  Tumor Biology, 2014
• Activation of phosphoinositide breakdown and elevation of intracellular calcium in a rat RBL-2H3 mast cell line by adenosine analogs: Involvement of A3-adenosine receptors?
  Drug Development Research, 1996